Back to search results

Observational Study on Menopause and HIV's Impact on Heart Health

This observational study aims to understand how menopause and HIV together might increase your risk for cardiovascular (heart and blood vessel) disease. Researchers will look at factors like insulin resistance (when your body doesn't use insulin properly), high blood pressure, high cholesterol, and hardening of the arteries in your neck (carotid atherosclerosis). They will also explore how inflammation in your body and your weight might play a role. You would be eligible to participate if you are a non-pregnant woman with HIV, are virally suppressed (HIV RNA <200 copies/mL), are on antiretroviral therapy, and have not had a hysterectomy or oophorectomy. The study will involve a whole body MRI (Magnetic Resonance Imaging) scan. The study's success will be measured by looking at markers of immune activation and inflammation from your blood work. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will observe and collect information without providing a specific treatment. It aims to enroll 90 women with HIV.
What's involved
You would undergo a whole body MRI scan and have blood drawn for analysis of immune activation and inflammation markers.
Compensation
Not stated in the trial record.
Follow-up
Markers of immune activation and inflammation will be measured from blood work collected at a single scheduled study visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07284082

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

Recruiting
Not specifiedAges 18+Observational
University of California, San Francisco
~90 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Whole body MRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Markers of immune activation and inflammation
Measured over These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point.

Conditions

HIV
Menopause
Cardiovascular (CV) Risk
Carotid Arteriosclerosis
Body Composition

Explore related trials

Cardiovascular DisorderCarotid atherosclerosisHIV InfectionMenopause present

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Rebecca Abelman, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Rebecca A Abelman, MD
[email protected]
415-221-4810 · ext. 23613
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.

Exclusion

Women who are not virally suppressed (HIV RNA \>200 copies/mL)
Women who are not on antiretroviral therapy
Women who have a history of hysterectomy or oophorectomy
Women who are receiving treatment for active cancer or tuberculosis

What this trial measures

  • Markers of immune activation and inflammationThese markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point.

    sCD14 (monocyte activation), sCD163 (M2 macrophage activation), CRP (inflammation), IL-6 (inflammation), IP-10 (interferon-inducible protein), TNFα (inflammation), MCP-1 (inflammation), sTNFRI \& RII (inflammation). There are no units as they will be normalized based upon their interquartile range.